Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)

Clinical Study Centers, LLC

Status

Completed

Conditions

Attention Deficit Hyperactivity Disorder

Sleep

Treatments

Drug: lisdexamfetamine dimesylate

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00807222

IST-NRP104

Details and patient eligibility

About

This study involves research to test how Vyvanse (study drug) affects sleep in 24 children aged 6 to 12 years who have ADHD. Vyvanse is approved by the FDA for the treatment ADHD of in children aged 6 to 12 years. The experimental part of this study is to determine how Vyvanse affects sleep.

Full description

Treatment with psychostimulants has been associated with sleep disturbances, including both sleep onset and maintenance problems, in children with ADHD. This analysis evaluated the effect of lisdexamfetamine dimesylate (LDX) on sleep in children with ADHD.

This single center, double-blind, placebo-controlled, parallel-group trial enrolled children aged 6-12 years with a DSM-IV-TR diagnosis of ADHD. The study included a screening period, 1-week washout, 3-week open-label LDX dose optimization phase, and a 4-week double-blind treatment phase in which subjects were randomized to placebo or active LDX treatment at 30, 50, or 70 mg/d. Polysomnograph and actigraph measures as well as assessments of subjective sleep parameters were performed in all subjects prior to treatment and reassessed after treatment with either LDX or placebo.

Enrollment

24 patients

Sex

All

Ages

6 to 12 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female subject 6 to 12 years of age, inclusive
Subject meets DSM-IV-TR criteria for a primary diagnosis of ADHD
Female subjects of childbearing potential (FOCP) must have a negative urine pregnancy test
Subject must be in general good health
Subject's parent or legally authorized guardian provides signature of informed consent, and there is documentation of assent by the subject.
Subject and parent/caregiver are willing and able to comply with all the testing and requirements defined in the protocol.
Subject is generally functioning academically at age-appropriate levels
Subject is able to swallow a capsule.
Subject and parent/guardian are willing to comply with entire visit schedule for the study and Sleep Hygiene Instructions

Exclusion criteria

Subject has a comorbid psychiatric diagnosis that contraindicates VyvanseTM treatment or would confound efficacy or safety assessments.
Subject has any comorbid illness that could interfere with participation in the study.
Subject is a known non-responder to an adequate trial of stimulant medication for ADHD.
Subject has history of symptoms or has an identified sleep disorder
Subject has a history of seizure during the last 2 years
Subject is significantly overweight or obese
Subject has any clinically significant ECG or laboratory abnormalities at screening or baseline.
Subject has any specific cardiac condition or family history of cardiac disease
Subject is taking medications that affect blood pressure or heart rate (except current ADHD therapy, if any).
Subject has a positive urine drug result at screening (except current ADHD therapy, if any).
Subject is hypertensive.
Subject has any documented adverse reactions, allergy, or intolerance to amphetamines or dextroamphetamines.
Subject is taking exclusionary medications
Subject currently has (or had a history in the previous 12 months) a drug dependence or substance abuse disorder
Subject has taken another investigational product or taken part in a clinical trial within the 30 days prior to Screening (Visit 1).